Stockscreener 앱 받기
55.91
1.73%
0.905
전일 마감가:
$55.00
열려 있는:
$55.37
하루 거래량:
1.91M
Relative Volume:
0.18
시가총액:
$114.00B
수익:
$48.48B
순이익/손실:
$7.27B
주가수익비율:
15.69
EPS:
3.5626
순현금흐름:
$11.91B
1주 성능:
+3.61%
1개월 성능:
-5.90%
6개월 성능:
+2.27%
1년 성능:
+19.86%
1일 변동 폭
$55.02
$56.19
1주일 범위
$53.99
$56.59
52주 변동 폭
$42.52
$62.89
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
55.83 | 112.31B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,131.75 | 996.31B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
246.62 | 580.14B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
240.62 | 415.00B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.53 | 297.86B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.90 | 292.17B | 54.66B | 13.58B | 16.05B | 7.0171 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Revisiting Stock Picks Intel, Progressive, Bristol Myers Squibb -- Barrons.com - Moomoo
Bristol Myers Follows Novartis, Sues Arkansas Over Pharmacy Law - Bloomberg Law News
Bristol Myers Squibb sets next earnings date, shares trade steadily on NYSE - Ad-hoc-news.de
Opdivo from Bristol-Myers Squibb Co.immunotherapy mainstay with new combo data - Ad-hoc-news.de
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Bristol-Myers Squibb Company (BMY) and SystImmune Announce Results from Analyses of Iza-bren Studies - Insider Monkey
Bristol Myers Squibb weighs dividend reset, shares trade near recent lows - AD HOC NEWS
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda - GlobeNewswire Inc.
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol-Myers Squibb Company (BMY) Stock Analysis: Exploring the 16.81% Upside Potential for Investors - DirectorsTalk Interviews
Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now - Kavout | AI
Bristol-Myers Squibb StockLong-term pipeline and business model under review - AD HOC NEWS
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Bristol-Myers Squibb Co (CELG_r) Institutional Confidence - TradingKey
Bristol-Myers Squibb Co (CELG_r) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bristol-Myers Squibb Co (CELG_r) Valuation: PE, PB & Fair Value Analysis - TradingKey
CHEMUNG CANAL TRUST CO's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bristol-Myers Squibb Company: Target Price Consensus and Analysts Recommendations | BMY | US1101221083 - marketscreener.com
Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend at $0.63 per Share - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Faithward Advisors, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (CELG_r) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes - Yahoo Finance
Measured Wealth Private Client Group, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Co (BMY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bristol-Myers Squibb Co (BMY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bristol-Myers Squibb Co (CELG_r) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bristol Myers Squibb declares $0.63 quarterly dividend - Investing.com
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol Myers Squibb declares $0.63 quarterly dividend By Investing.com - Investing.com Canada
Bristol-Myers Squibb Co (CELG_r) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries - PR Newswire UK
BREYANZI® CAR T Cell Therapy Monitoring and Activity Updates Approved in Canada - PR Newswire Canada
Bristol-Myers Squibb Co (BMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bristol-Myers Squibb Co (BMY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bristol-Myers Squibb Co (BMY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio? - Yahoo Finance
Bristol-Myers Squibb—ad spending, facts and profile - Ad Age
Psoriasis around the world - Bristol Myers Squibb
David Elkins - Bristol Myers Squibb
Bristol Myers Squibb (BMY) Stock Could Be 10.7% Undervalued After Kidney Cancer Trial Expansion - simplywall.st
Chris Boerner, Board Chair and Chief Executive Officer - Bristol Myers Squibb
Cari Gallman - Bristol Myers Squibb
Karin Shanahan - Bristol Myers Squibb
Technologies - Bristol Myers Squibb
BMY Faces Headline Risk Amid Medicare Drug Price Negotiation Pro - GuruFocus
A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb - Yahoo Finance
Panagora Asset Management Inc. Raises Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 10.41% Upside in the Healthcare Giant - DirectorsTalk Interviews
Bristol-Myers Squibb Stock (US1078421011): Dividend Safety Under the Microscope - AD HOC NEWS
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.92%
자본화:
|
볼륨(24시간):